

Lemzoparlimab

Cat. No.:	HY-P99026
CAS No.:	2377483-71-9
Molecular Weight:	145580.00
Target:	CD47
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity [1].
In Vitro	Lemzoparlimab is a highly differentiated red blood cells (RBCs)-sparing CD47 antibody with unique epitope. Lemzoparlimab binds to the CD47 antigen, blocks the CD47-SIRP α signaling pathway, thereby enhancing the phagocytosis against tumor cells of macrophages. Lemzoparlimab minimizes binding to normal RBCs, thereby reducing hemagglutination that may be caused by some CD47 mAbs ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Lemzoparlimab inhibits the tumor growth, exhibits antitumor effect in mouse acute myeloid leukemia (AML) xenograft models, and prolongs the survival of mice ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Jiang Z, et al., Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021 Oct 30;14(1):180.

[2]. Amitkumar Mehta, et al. Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin's Lymphoma: Initial Clinical Results. Blood (2021) 138 (Supplement 1): 3542.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA